Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHYF) Debt to Equity (2017 - 2019)

Historic Debt to Equity for Innate Pharma (IPHYF) over the last 3 years, with Q4 2019 value amounting to $0.09.

  • Innate Pharma's Debt to Equity rose 15311.15% to $0.09 in Q4 2019 from the same period last year, while for Dec 2019 it was $0.09, marking a year-over-year increase of 15311.15%. This contributed to the annual value of $0.09 for FY2019, which is 15311.15% up from last year.
  • Innate Pharma's Debt to Equity amounted to $0.09 in Q4 2019, which was up 15311.15% from $0.03 recorded in Q4 2018.
  • In the past 5 years, Innate Pharma's Debt to Equity ranged from a high of $0.09 in Q4 2019 and a low of $0.03 during Q4 2018
  • Moreover, its 3-year median value for Debt to Equity was $0.07 (2017), whereas its average is $0.06.
  • Per our database at Business Quant, Innate Pharma's Debt to Equity plummeted by 5012.83% in 2018 and then soared by 15311.15% in 2019.
  • Innate Pharma's Debt to Equity (Quarter) stood at $0.07 in 2017, then tumbled by 50.13% to $0.03 in 2018, then soared by 153.11% to $0.09 in 2019.
  • Its last three reported values are $0.09 in Q4 2019, $0.03 for Q4 2018, and $0.07 during Q4 2017.